Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Ramipril Versus Carvedilol in Duchenne and Becker Patients

Phase 4

Conditions: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy

Interventions: Drug: ramipril
Drug: carvedilol

First Posted Date: 2009-01-09

Last Posted Date: 2016-01-28

Lead Sponsor: Catholic University, Italy

Target Recruit Count: 194

Registration Number: NCT00819845

Locations: 🇮🇹
Unione Italiana lotta Distrofia Muscolare, Rome, Italy

Coreg CR, Blood Vessel Stiffness and Blood Vessel Function

Phase 4

Conditions: Endothelial Function
Diabetes Mellitus
Hypertension

Interventions: Drug: metoprolol extended release
Drug: carvedilol

First Posted Date: 2008-08-12

Last Posted Date: 2011-02-10

Lead Sponsor: State University of New York - Downstate Medical Center

Target Recruit Count: 40

Registration Number: NCT00732511

Locations: 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

Phase 4

Completed

Conditions: Hypertension
Coronary Artery Disease

Interventions: Drug: Nebivolol
Drug: Carvedilol

First Posted Date: 2008-05-07

Last Posted Date: 2010-09-28

Lead Sponsor: Forest Laboratories

Target Recruit Count: 39

Registration Number: NCT00673075

Locations: 🇺🇸
Forest Investigative Site, Carrollton, Texas, United States
🇺🇸
Forest Investigator Site, Florence, South Carolina, United States

Comparison of Blood Pressure Medications on Metabolism

Phase 4

Completed

Conditions: Diabetes

Interventions: Drug: carvedilol
Drug: metoprolol

First Posted Date: 2008-03-25

Last Posted Date: 2023-12-26

Lead Sponsor: University of New Mexico

Target Recruit Count: 22

Registration Number: NCT00642434

Locations: 🇺🇸
UNMHSC, Albuquerque, New Mexico, United States

The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy

Phase 4

Conditions: Duchenne Muscular Dystrophy
Cardiomyopathies

Interventions: Drug: Carvedilol

First Posted Date: 2008-02-05

Last Posted Date: 2008-02-05

Lead Sponsor: Suzuka Hospital

Target Recruit Count: 60

Registration Number: NCT00606775

Locations: 🇯🇵
Suzuka Hospial, Suzuka, Mie, Japan

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure

Phase 4

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: carvedilol
Drug: bisoprolol
Drug: Nebivolol

First Posted Date: 2007-08-17

Last Posted Date: 2010-09-16

Lead Sponsor: Centro Cardiologico Monzino

Target Recruit Count: 60

Registration Number: NCT00517725

Locations: 🇮🇹
Centro Cardiologico Monzino, University of Milan, Milan, Italy

Danish Carvedilol Study in Portal Hypertension

Phase 3

Completed

Conditions: Cirrhosis
Portal Hypertension

Interventions: Drug: carvedilol
Drug: propranolol

First Posted Date: 2007-06-28

Last Posted Date: 2009-08-10

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 40

Registration Number: NCT00493480

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

Phase 2

Terminated

Conditions: Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2007-03-08

Last Posted Date: 2016-08-29

Lead Sponsor: Egalet Ltd

Target Recruit Count: 14

Registration Number: NCT00444834

Locations: 🇩🇰
Site 02, Esbjerg, Denmark
🇩🇰
Site 01, Frederiksberg, Denmark

"The Evaluation of Stimulant Withdrawal"

Phase 2

Withdrawn

Conditions: Anxiety
Substance Addiction
Relapse

Interventions: Drug: Coreg

First Posted Date: 2007-03-05

Last Posted Date: 2019-01-31

Lead Sponsor: Aaron J. Janowsky

Registration Number: NCT00442923

Locations: 🇺🇸
US Veterans Hospital, Portland, Oregon, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy